疫情|深度解读｜首个新冠口服药来了，对疫情有何影响？( 二 ) 疫情|新冠|mol|默克

[10] Khoo SH, Fitzgerald R, Fletcher T, Ewings S, Jaki T, LyonR, Downs N, Walker L, Tansley-Hancock O, Greenhalf W, Woods C, Reynolds H,Marwood E, Mozgunov P, Adams E, Bullock K, Holman W, Bula MD, Gibney JL,Saunders G, Corkhill A, Hale C, Thorne K, Chiong J, Condie S, Pertinez H,Painter W, Wrixon E, Johnson L, Yeats S, Mallard K, Radford M, Fines K, Shaw V,Owen A, Lalloo DG, Jacobs M, Griffiths G. Optimal dose and safety ofMolnupiravir in patients with early SARS-CoV-2: a Phase I, open-label,dose-escalating, randomized controlled study. J Antimicrob Chemother. 2021 Aug27:dkab318. doi: 10.1093/jac/dkab318. Epub ahead of print. PMID: 34450619.
[11] Painter GR, Natchus MG, Cohen O, Holman W, Painter WP.Developing a direct acting, orally available antiviral agent in a pandemic: theevolution of Molnupiravir as a potential treatment for COVID-19. Curr OpinVirol. 2021 Jun 18;50:17-22. doi: 10.1016/j.coviro.2021.06.003. Epub ahead ofprint. PMID: 34271264; PMCID: PMC8277160.
[12] Fischer W, Eron JJ, Holman W, Cohen MS, Fang L, SzewczykLJ, Sheahan TP, Baric R, Mollan KR, Wolfe CR, Duke ER, Azizad MM, Borroto-EsodaK, Wohl DA, Loftis AJ, Alabanza P, Lipansky F, Painter WP. Molnupiravir, anOral Antiviral Treatment for COVID-19. medRxiv [Preprint]. 2021 Jun17:2021.06.17.21258639. doi: 10.1101/2021.06.17.21258639. PMID: 34159342;PMCID: PMC8219109.
[13]Fei Zhou. et al.Clinicalcourse and risk factors for mortality of adult inpatients with COVID-19 inWuhan, China: a retrospective cohort study, The Lancet,395,1054-1062(2020）
[14]Dawei Wang. et al.ClinicalCharacteristics of 138 Hospitalized Patients With 2019 NovelCoronavirus–Infected Pneumonia in Wuhan, China, JAMA,2020;323(11）:1061-1069. doi:10.1001/jama.2020.1585
[15]Deena Beasley. 2021. Merckto Seek FDA OK for Its COVID Pill After Trial Stopped Early.MedScape. https://www.medscape.com/viewarticle/959950?uac=301446HN&faf=1&sso=true&impID=3678138&src=https://www.laoziliao.net/health/info/mkm_covid_update_210930_MSCPEDIT
[16]Cevik M, Tate M, Lloyd O etal. SARS-CoV-2, SARS-CoV, and MERS-CoV viral loaddynamics, duration of viral shedding, and infectiousness: a systematic reviewand meta-analysis. Lancet Microbe 2021; 2: e13–22.
[17]Chen P, Nirula A, Heller B,et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.N Engl J Med 2021;384(3）:229–37.
[18]Liu Y, Yan L-M, Wan L, etal. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis2020;20(6）:656–7.
[19]https://www.medscape.com/viewarticle/959950?uac=301446HN&faf=1&sso=true&impID=3678138&src=https://www.laoziliao.net/health/info/mkm_covid_update_210930_MSCPEDIT
[20]Dougan M, Nirula A et al; BLAZE-1 Investigators.Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19. N Engl J Med. 2021Jul 14:NEJMoa2102685. doi: 10.1056/NEJMoa2102685. Epub ahead of print. PMID:34260849; PMCID: PMC8314785.
[21]Peter Chen et al. SARS-CoV-2Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med ， October 28 ， 2020.
[22]Cohen MS, Nirula Aet al; BLAZE-2 Investigators. Effect of Bamlanivimab vs Placeboon Incidence of COVID-19 Among Residents and Staff of Skilled Nursing andAssisted Living Facilities: A Randomized Clinical Trial. JAMA. 2021 Jul6;326(1):46-55. doi: 10.1001/jama.2021.8828. PMID: 34081073; PMCID: PMC8176388.
[23]Kalil AC, Patterson TF etal;ACTT-2 Study Group Members. Baricitinib plus Remdesivir for HospitalizedAdults with Covid-19. N Engl J Med. 2021 Mar 4;384(9):795-807. doi:10.1056/NEJMoa2031994. Epub 2020 Dec 11. PMID: 33306283; PMCID: PMC7745180.
[24]Weinreich, David M et al.“REGEN-COV Antibody Combination and Outcomes in Outpatients withCovid-19.” The New England journal of medicine, 10.1056/NEJMoa2108163. 29Sep. 2021, doi:10.1056/NEJMoa2108163
[25] O'Brien MP, Forleo-Neto E,Musser BJ, et al. Subcutaneous REGEN-COV Antibody Combination to PreventCovid-19. N Engl J Med. 2021;385(13):1184-1195. doi:10.1056/NEJMoa2109682
[26]O'Brien, Meagan P et al. “Subcutaneous REGEN-COV Antibody Combination in EarlySARS-CoV-2 Infection.” medRxiv : the preprintserver for health sciences 2021.06.14.21258569. 14 Jun. 2021,doi:10.1101/2021.06.14.21258569. Preprint.